| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total comprehensive loss | -13,305 | -11,850 | ||
| Earnings per share, basic | -0.25 | -0.34 | ||
| Earnings per share, diluted | -0.25 | -0.34 | ||
| Weighted average number of shares outstanding, basic | 53,951,371 | 46,686,239 | ||
| Weighted average number of shares outstanding, diluted | 53,951,371 | 46,686,239 | ||
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)